文献速递神经肿瘤

过表达SYNGR1通过抑制FGF1介导的脂滴积聚与细胞骨架重塑抑制GBM进展

Engineering overexpressing SYNGR1 inhibited the progression of GBM cells by suppressing the intracellular FGF1-mediated LDs accumulation and cytoskeleton remodeling.
PubMed 文献 · J Neurooncol · 2025-06-06

该研究探讨过表达突触回旋蛋白1(SYNGR1)对胶质母细胞瘤(GBM)细胞恶性行为的影响及机制。体外实验表明过表达SYNGR1可抑制GBM细胞脂滴积聚、增殖、侵袭和黏附,体内实验可抑制颅内胶质瘤生长并延长荷瘤小鼠生存。机制上SYNGR1通过下调胞内FGF1抑制脂滴积聚与细胞骨架重塑,而FGF1过表达可逆转该抗胶质瘤效应。

要点

  • GBM中SYNGR1表达显著降低,过表达可抑制肿瘤恶性行为。
  • SYNGR1抗胶质瘤效应依赖下调胞内FGF1介导的脂滴积聚与骨架重塑。
  • FGF1过表达可逆转SYNGR1的抗胶质瘤作用。

核心结论

  • 胞内FGF1在维持脂滴稳态和肌动蛋白骨架中起重要作用,促进GBM恶性进展。
  • 工程化过表达SYNGR1通过抑制FGF1介导的脂滴积聚和细胞骨架重塑抑制GBM恶性生物学行为并促进凋亡。

研究设计与样本

  • 利用UCSC Xena和GEPIA数据库分析SYNGR1表达与胶质瘤患者生存时间的相关性。
  • 用慢病毒建立稳定过表达SYNGR1、FGF1或两者共表达的胶质瘤细胞(U251、LN229、U118)。
  • 采用CCK8、EdU、免疫荧光、克隆形成、黏附及Transwell实验检测增殖、侵袭和细胞骨架。
  • 用尼罗红脂滴红色荧光法检测胞内脂滴,流式细胞术评估细胞周期和凋亡率。
  • 用Gl261细胞和C57BL/6小鼠构建胶质母细胞瘤模型,动物MRI检查肿瘤大小。

主要发现

  • SYNGR1在GBM中表达显著降低。
  • 过表达SYNGR1在体外显著抑制GBM细胞脂滴积聚、增殖、侵袭、黏附等恶性过程。
  • 过表达SYNGR1在体内抑制颅内胶质瘤生长并延长C57BL/6模型小鼠生存。
  • 过表达SYNGR1通过下调胞内FGF1抑制脂滴积聚和重塑细胞骨架发挥抗胶质瘤作用。
  • FGF1过表达可逆转SYNGR1的抗胶质瘤效应。

临床怎么用

  • SYNGR1低表达与GBM恶性进展相关,可作为潜在预后或干预靶点探索。
  • 靶向FGF1介导的脂滴积聚与细胞骨架重塑可能成为GBM治疗策略方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glioblastoma (GBM) is the most common and aggressive glioma subtype in adults, characterized by disrupted lipid homeostasis. The accumulation of lipid droplets (LDs) is involved in the actin cytoskeleton remodeling in different types of cells, the intracellular fibroblast growth factor 1 (FGF1) plays an important role in this process. The stability of cytoskeleton is crucial for the proliferation, invasion and other malignant behavior of GBM. The synaptic gyrus protein 1 (synaptogyrin 1, SYNGR1) is closely correlated with the progression of various tumours, but there have been no reports of research in the field of glioma. This research was conducted to investigate whether the overexpression of SYNGR1 was involved in regulating the malignant biological behaviour of GBM cells and its potential regulatory mechanism, especially whether the LDs accumulation is involved in the remodeling of the actin cytoskeleton in GBM cells. METHODS: The UCSC Xena database and GEPIA database were used to analyze the correlation between the expression level of SYNGR1 and the survival time of glioma patients. Engineering Lentiviruses were used to establish cells with stable overexpression of SYNGR1, FGF1, or both. The proliferation, invasion, and cytoskeleton of glioma cells (U251, LN229, U118) were detected by cell counting kit-8 (CCK8), 5-ethynyl-2'-deoxyuridine (EdU), immunofluorescence(IF), colony formation, adhesion, and transwell assays. Intracellular LDs were detected by the lipid droplet red fluorescence assay with Nile red. The cell cycle distribution and apoptosis rate of the cells were assessed using flow cytometry analysis. Bioinformatics analysis, IF, RNA sequencing, and western blot analysis were used to measure the expression levels of target proteins. The protein from HA and HT22 cell lines served as control was detected by western blot analysis. The Gl261 cell line and C57BL/6 mouse were used to construct C57BL/6 mouse glioblastoma model. Animal MRI was used to examine tumor size. RESULTS: SYNGR1 expression was significantly reduced in GBM. Overexpression of SYNGR1 significantly inhibited the LDs accumulation, proliferation, invasion, adhesion, and other malignant processes in GBM cells in vitro. Moreover, SYNGRI overexpression inhibited the growth of intracranial gliomas in vivo and prolonged survival of C57BL/6 model mice. Mechanistic exploration revealed that the overexpression of SYNGR1 had an antiglioma effect by inhibiting the LDs accumulation and remodeling the cytoskeleton via the downregulation of the intracellular FGF1, while FGF1 overexpression could reverse the antiglioma effect of SYNGR1. CONCLUSIONS: The intracellular FGF1 played an important role in maintaining the homeostasis of LDs and the actin cytoskeleton, which promoted the malignant progression of GBM cells. Engineering overexpressing SYNGR1 could effectively inhibit the malignant biological behaviors, such as the proliferation, adhesion, and invasion, as well as promote the apoptosis of glioma cells by suppressing the intracellular FGF1-mediated LDs accumulation and cytoskeleton remodeling.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Wang J, Yang Q, Li X, et al. Engineering overexpressing SYNGR1 inhibited the progression of GBM cells by suppressing the intracellular FGF1-mediated LDs accumulation and cytoskeleton remodeling. J Neurooncol. 2025. PMID: 40478501. doi:10.1007/s11060-025-05095-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。